234 related articles for article (PubMed ID: 38071335)
1. Dysregulated cholesterol regulatory genes in hepatocellular carcinoma.
Cao D; Liu H
Eur J Med Res; 2023 Dec; 28(1):580. PubMed ID: 38071335
[TBL] [Abstract][Full Text] [Related]
2. ZEB1 enhances Warburg effect to facilitate tumorigenesis and metastasis of HCC by transcriptionally activating PFKM.
Zhou Y; Lin F; Wan T; Chen A; Wang H; Jiang B; Zhao W; Liao S; Wang S; Li G; Xu Z; Wang J; Zhang J; Ma H; Lin D; Li Q
Theranostics; 2021; 11(12):5926-5938. PubMed ID: 33897890
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-dependent expression of MAP17 coordinates the Warburg effect to tumor growth in hepatocellular carcinoma.
Dong F; Li R; Wang J; Zhang Y; Yao J; Jiang SH; Hu X; Feng M; Bao Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):121. PubMed ID: 33832535
[TBL] [Abstract][Full Text] [Related]
4. RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.
Chan LK; Ho DW; Kam CS; Chiu EY; Lo IL; Yau DT; Cheung ET; Tang CN; Tang VW; Lee TK; Wong CC; Chok KS; Chan AC; Cheung TT; Wong CM; Ng IO
J Hepatol; 2021 Feb; 74(2):360-371. PubMed ID: 32918955
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
Ding H; Liu J; Zou R; Cheng P; Su Y
J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
[TBL] [Abstract][Full Text] [Related]
6. The role of hypoxia inducible factor-1 in hepatocellular carcinoma.
Luo D; Wang Z; Wu J; Jiang C; Wu J
Biomed Res Int; 2014; 2014():409272. PubMed ID: 25101278
[TBL] [Abstract][Full Text] [Related]
7. Integrated analyses identify miR-34c-3p/MAGI3 axis for the Warburg metabolism in hepatocellular carcinoma.
Weng Q; Chen M; Yang W; Li J; Fan K; Xu M; Weng W; Lv X; Fang S; Zheng L; Song J; Zhao Z; Fan X; Ji J
FASEB J; 2020 Apr; 34(4):5420-5434. PubMed ID: 32080912
[TBL] [Abstract][Full Text] [Related]
8. Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Zhao C; Wang B; Liu E; Zhang Z
Cell Commun Signal; 2020 Aug; 18(1):131. PubMed ID: 32831114
[TBL] [Abstract][Full Text] [Related]
9. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
[TBL] [Abstract][Full Text] [Related]
10. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
11. CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect.
Zheng J; Yan X; Lu T; Song W; Li Y; Liang J; Zhang J; Cai J; Sui X; Xiao J; Chen H; Chen G; Zhang Q; Liu Y; Yang Y; Zheng K; Pan Z
J Exp Clin Cancer Res; 2023 Mar; 42(1):63. PubMed ID: 36922872
[TBL] [Abstract][Full Text] [Related]
12. LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.
Chen Z; Chen L; Sun B; Liu D; He Y; Qi L; Li G; Han Z; Zhan L; Zhang S; Zhu K; Luo Y; Chen L; Zhang N; Guo H
Mol Metab; 2021 Sep; 51():101230. PubMed ID: 33823318
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA‑29c‑3p acts as a tumor suppressor gene and inhibits tumor progression in hepatocellular carcinoma by targeting TRIM31.
Lv T; Jiang L; Kong L; Yang J
Oncol Rep; 2020 Mar; 43(3):953-964. PubMed ID: 32020206
[TBL] [Abstract][Full Text] [Related]
14. Squalene epoxidase (SQLE) promotes the growth and migration of the hepatocellular carcinoma cells.
Sui Z; Zhou J; Cheng Z; Lu P
Tumour Biol; 2015 Aug; 36(8):6173-9. PubMed ID: 25787749
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target.
Wu Y; Meng X; Huang C; Li J
Tumour Biol; 2015 Jun; 36(6):4063-74. PubMed ID: 25926383
[TBL] [Abstract][Full Text] [Related]
16. Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling.
Chen T; Yuan Z; Lei Z; Duan J; Xue J; Lu T; Yan G; Zhang L; Liu Y; Li Q; Zhang Y
Theranostics; 2022; 12(17):7450-7464. PubMed ID: 36438486
[No Abstract] [Full Text] [Related]
17. Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy.
Yu S; Wang Y; Jing L; Claret FX; Li Q; Tian T; Liang X; Ruan Z; Jiang L; Yao Y; Nan K; Lv Y; Guo H
Cancer Lett; 2017 Dec; 411():82-89. PubMed ID: 28987386
[TBL] [Abstract][Full Text] [Related]
18. LINC01419 promotes cell proliferation and metastasis in hepatocellular carcinoma by enhancing NDRG1 promoter activity.
Dang H; Chen L; Tang P; Cai X; Zhang W; Zhang R; Huang A; Tang H
Cell Oncol (Dordr); 2020 Oct; 43(5):931-947. PubMed ID: 32557341
[TBL] [Abstract][Full Text] [Related]
19. Unspliced XBP1 contributes to cholesterol biosynthesis and tumorigenesis by stabilizing SREBP2 in hepatocellular carcinoma.
Wei M; Nurjanah U; Herkilini A; Huang C; Li Y; Miyagishi M; Wu S; Kasim V
Cell Mol Life Sci; 2022 Aug; 79(9):472. PubMed ID: 35933495
[TBL] [Abstract][Full Text] [Related]
20. Functional long non-coding RNAs in hepatocellular carcinoma.
Xie C; Li SY; Fang JH; Zhu Y; Yang JE
Cancer Lett; 2021 Mar; 500():281-291. PubMed ID: 33129957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
